Lexington, KY, United States of America

Jurgen Rohr

USPTO Granted Patents = 6 

Average Co-Inventor Count = 4.8

ph-index = 1

Forward Citations = 20(Granted Patents)


Location History:

  • Georgetown, KY (US) (2008 - 2010)
  • Lexington, KY (US) (2016 - 2023)

Company Filing History:


Years Active: 2008-2023

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Jurgen Rohr: Innovator in Cancer Treatment

Introduction

Jurgen Rohr is a notable inventor based in Lexington, KY (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of mithramycin derivatives. With a total of 6 patents, his work focuses on enhancing the selectivity and anti-cancer activity of these compounds.

Latest Patents

Rohr's latest patents include the development of mithramycin derivatives that exhibit increased selectivity and anti-cancer activity. These derivatives, specifically mithramycin short side chain ketone (SK) and diketone (SDK) derivatives, are designed for the treatment of cancer and neuro-diseases associated with aberrant erythroblast transformation-specific transcription factor. The unique properties of these derivatives allow for increased selectivity toward ETS transcription factors. Additionally, he has developed mithramycin oxime derivatives and mithramycin hydrazine derivatives, which are also aimed at treating cancers and neuro-diseases.

Career Highlights

Throughout his career, Jurgen Rohr has worked with esteemed institutions such as the University of Kentucky Research Foundation and Universidad De Oviedo. His research has been pivotal in advancing the understanding and treatment of various cancers.

Collaborations

Rohr has collaborated with notable colleagues, including Markos Leggas and Oleg Tsodikov, contributing to a rich exchange of ideas and innovations in his field.

Conclusion

Jurgen Rohr's contributions to cancer treatment through his innovative patents and collaborations highlight his commitment to advancing medical science. His work continues to pave the way for new therapeutic options in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…